iStat Biomedical Co., Ltd. - Epigene

iStat, Epigene, Epigenebio, Cervical cancer test, Oral cancer test, Cancer methylation test, Epigenetic IVD assay, Non-invasive early cancer detection, DNA Methylatoin, 日祥, 甲基化基因檢測, 癌症基因檢測

iStat- Epigenetic IVD assay for cancer DNA methylation biomarkers. iStat is a Taiwan-based biotechnology company specialized in the development and manufacturing of high quality gene methylation assay products for the early detection of cervical, oral, and bladder cancers. The company provides innovative IVD products for use in the clinical laboratories and solutions for medication managements. The company is actively seeking distributors in Europe, Middle East, and Latin America, and is discussing licensing potentials with some of the global companies.

Technology

 
  • iStat’s technology platform, Methylation-Specific-PCR (MSP), is a proprietary DNA-based technology that detects tumor-specific gene methylation with high precision and accuracy.
  • Aberrant DNA methylation has known to be associated with human cancers through epigenetic gene silencing of tumor suppressor and DNA repair genes. iStat’s MSP provides optimal solutions for physicians in cancer diagnosis and therapy monitoring.
  • iStat holds several patents and intellectual properties on the MSP technology which targets a broad portfolio of biomarkers designating for different products. 

Methylation Specific PCR (MSP)

Methylation-specific PCR can rapidly assess the methylation status of CpG sites within a CpG island. An MSP assay entails initial modification of DNA by sodium bisulfite, converting all unmethylated cytosines to uracil. Subsequently, modificated DNA amplified with primers specific for methylated DNA. The use of a Real Time Quantitative MSP enables highly accurate discrimination between positive and negative findings.

Features of iStat’s MSP:
  • High sensitivity - sensitively detects low levels methylated biomarkers.
  • High specificity - targets specific tumor markers.
  • Early detection - detects earlier stage precancerous lesions.
  • User friendly kit design and simplified assay procedures - shortens turn around time.
 

Assay Process

The MSP assays are performed on DNA isolated from patient samples. The extracted DNA is chemically treated to convert the unmethylated cytosines to uracil and subsequent PCR amplification with methylation specific primers allows for the quantitative measurement of methylated alleles. These results are subsequently used to report a clinically meaningful result to treating physicians.
  
 
iStat- Epigenetic IVD assay for cancer DNA methylation biomarkers. iStat is a Taiwan-based biotechnology company specialized in the development and manufacturing of high quality gene methylation assay products for the early detection of cervical, oral, and bladder cancers. The company provides innovative IVD products for use in the clinical laboratories and solutions for medication managements. The company is actively seeking distributors in Europe, Middle East, and Latin America, and is discussing licensing potentials with some of the global companies.
en